Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years

Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years

IntroductionThe International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders’ Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration.MethodsThis edition focused on...

Full description

Saved in:
Bibliographic Details
Main Authors: Lúcia Mamede, Roser Cantenys Sabà, Samya Van Coillie, Johan Prévot, Silvia Sánchez-Ramón, Cecilia Poli, Anne Barasa, Björn W. Schuller, Ayal Hendel, Nicolas Garcelon, Cornelis Boersma, Pamela Lee, Claire Booth, Luigi D. Notarangelo, Jose Drabwell, Nicholas L. Rider, Frank J. T. Staal, Siobhan O. Burns, Martin Van Hagen, Martine Pergent, Jacques G. Rivière, Nizar Mahlaoui
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
primary immunodeficiencies (PIDs)
inborn errors of immunity (IEI)
immunoglobulin replacement therapy (IGRT)
targeted therapies
gene therapy (GT)
digital health
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1596971/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionThe International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders’ Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration.MethodsThis edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care.ResultsThese discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years.DiscussionThese discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient’s needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.
ISSN:1664-3224

Similar Items